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Abstract
Background: Insulin resistance and early type-2 diabetes are highly prevalent. However, it is unknown whether IntralipidH
and sevoflurane protect the early diabetic heart against ischemia-reperfusion injury.
Methods: Early type-2 diabetic hearts from Sprague-Dawley rats fed for 6 weeks with fructose were exposed to 15 min of
ischemia and 30 min of reperfusion. IntralipidH (1%) was administered at the onset of reperfusion. Peri-ischemic sevoflurane
(2 vol.-%) served as alternative protection strategy. Recovery of left ventricular function was recorded and the activation of
Akt and ERK 1/2 was monitored. Mitochondrial function was assessed by high-resolution respirometry and mitochondrial
ROS production was measured by Amplex Red and aconitase activity assays. Acylcarnitine tissue content was measured and
concentration-response curves of complex IV inhibition by palmitoylcarnitine were obtained.
Results: IntralipidH did not exert protection in early diabetic hearts, while sevoflurane improved functional recovery.
Sevoflurane protection was abolished by concomitant administration of the ROS scavenger N-2-mercaptopropionyl glycine.
Sevoflurane, but not IntralipidH produced protective ROS during reperfusion, which activated Akt. IntralipidH failed to
inhibit respiratory complex IV, while sevoflurane inhibited complex I. Early diabetic hearts exhibited reduced carnitine-
palmitoyl-transferase-1 activity, but palmitoylcarnitine could not rescue protection and enhance postischemic functional
recovery. Cardiac mitochondria from early diabetic rats exhibited an increased content of subunit IV-2 of respiratory
complex IV and of uncoupling protein-3.
Conclusions: Early type-2 diabetic hearts lose complex IV-mediated protection by IntralipidH potentially due to a switch in
complex IV subunit expression and increased mitochondrial uncoupling, but are amenable to complex I-mediated
sevoflurane protection.
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Introduction
Type-2 diabetes mellitus is the most prevalent form of diabetes
(95%) and is characterized by elevated fasting blood glucose levels
due to insulin resistance [1]. Diabetic patients undergoing cardiac
and non-cardiac surgery suffer frequently from myocardial
dysfunction and infarction, cerebral stroke, and renal dysfunction.
The diabetic heart is already jeopardized by detrimental metabolic
derangements and thus at high risk of low cardiac output and
heart failure [2]. Mortality after myocardial infarction and cardiac
surgery is double in diabetic patients [3,4]. The cause for these
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complications in diabetic patients is the greater sensitivity of
diabetic hearts to ischemia-reperfusion injury. This has been
linked to impaired Akt signaling and GLUT4 trafficking, as well as
mitochondrial dysfunction [5,6,7,8].
Rahman and colleagues previously reported marked protection
of the heart against ischemia-reperfusion injury with a 70%
reduction in infarct size when IntralipidH was administered in high
doses (1%) at the onset of reperfusion [9]. Administration of
IntralipidH activates protection signaling pathways (ERK1/2, Akt
and GSK3b) and inhibits the mitochondrial permeability transi-
tion pore [10]. Recently, our group confirmed these results and
discovered that palmitoylcarnitine, the active fatty acid product of
IntralipidH, increases reactive oxygen species (ROS) production at
early reperfusion via the inhibition of complex IV of the
respiratory chain, and activates reperfusion injury salvage kinases
in healthy rat hearts [11]. However, whether IntralipidH can still
trigger protection against ischemia-reperfusion injury in the
context of insulin resistance and early type-2 diabetes is currently
unknown. Impairment or complete loss of cardioprotection by
pharmacological agents is well known in many diabetic models
[12]. Here, we hypothesized that IntralipidH would not trigger
ROS signaling at early reperfusion and hence elicit no protection
in diabetic hearts. We compared the IntralipidH effects with those
of sevoflurane, a potentially protective volatile anesthetic [13,14].
For our experiments, we have chosen the fructose-fed rat model
[15], which is a dietary model of the metabolic syndrome and of
the early changes associated with type-2 diabetes.
Materials and Methods
All materials were from Sigma-Aldrich Canada (Oakville ON,
Canada) unless otherwise stated.
Animal ethics statement
The investigation conforms to the Guide for the Care and Use
of Laboratory Animals published by the US National Institutes of
Health (NIH Publication, 8th Edition, 2011) and was approved by
the University of Alberta Animal Policy and Welfare Committee.
Dietary model of type-2 diabetes mellitus using fructose-
feeding [16]
Male Sprague-Dawley rats (8 weeks old, from the Biosciences
breeding colony, University of Alberta, Edmonton, Canada) were
fed for 6 weeks with standard chow (49% maize farina, protein
23.4%, fat 10%; PicoLabH Laboratory Rodent diet 5LOD)
combined with 10% fructose dissolved in the drinking water.
The healthy control group consisted of age-matched rats fed with
standard chow and tap water. After 6 weeks of fructose feeding,
glucose, insulin and triglyceride blood concentrations were
determined and compared to age-matched rats fed with standard
chow. Briefly, after overnight fasting, 200 mL blood samples were
collected into heparinized tubes (Natelson micro blood collecting
tubes, Fisher Scientific, Ottawa ON, Canada) and plasma aliquots
were stored at 220uC. Insulin in plasma was measured using the
Insulin (rat) Ultrasensitive ELISA immunoassay (ALPCO Diag-
nostics, Salem NH, USA), triglycerides in plasma were measured
by the WAKO Triglyceride E Kit method (Wako Chemicals,
Richmond VA, USA), and glucose in plasma was measured using
PGO enzymes and o-dianisidine as a colorimetric substrate
(Sigma-Aldrich). The quantitative insulin-sensitivity check index
(QUICKI) was calculated from fasting glucose (in mg/dL) and
fasting insulin concentrations (in mIU/mL) as follows: QUICKI =
1/(log [fasting insulin] + log [fasting glucose]) [17].
Working heart perfusions
Rats (14 weeks of age) were anesthetized with pentobarbital
(150 mg/kg, i.p.). Each heart was rapidly removed and perfused
initially in a non-working Langendorff mode with Krebs-Henseleit
solution for 10 min. The working mode perfusion was subse-
quently established (11.5 mmHg preload, 80 mmHg afterload,
5 Hz paced rate) with a recirculating perfusate of 100 mL (37uC,
pH 7.4) gassed with 95% O2/5% CO2 mixture that consisted of a
modified Krebs-Henseleit solution containing (mmol/L): KCl
(4.7), NaCl (118), KH2PO4 (1.2), MgSO4 (1.2), CaCl2 (2.5),
NaHCO3 (25), glucose (11), palmitate (1.2, pre-bound to 3%
bovine serum albumin) and insulin 100 mU/L [18]. All hearts
were subjected to 15 min of 37uC zero-flow ischemia and 30 min
of reperfusion (IR). Cardiac output (mL/min) and aortic flow
(mL/min) were measured using ultrasonic flow probes (Transonic
T206, Transonic Systems Inc., Ithaca, NY) placed in the left atrial
inflow and the aortic outflow lines. Left ventricular work (mL/
min?mmHg) was calculated as LVW = cardiac output N (aortic
systolic pressure 2 preload). Coronary flow (ml/min) was
calculated as the difference between cardiac output and aortic
flow. Measurements were averaged for the pre- and postischemic
periods. Hearts were randomly assigned to the following groups:
(1) untreated diabetic hearts (ff-IR) (2) diabetic hearts treated with
IntralipidH1% (Baxter, Mississauga ON Canada) administered at
the time of reperfusion, ff-IR/IL) [11] (3) diabetic hearts treated
with sevoflurane (2 vol.-%, bubbled into the perfusate) adminis-
tration 15 min before ischemia and during reperfusion (ff-IR/
SEV) [19]. Additional two groups served to assess the involvement
of ROS, namely diabetic hearts treated with sevoflurane (2 vol.-%)
plus concomitant N-2-mercaptopropionyl glycine (MPG; 10 mM)
(ff-IR/SEV+MPG) and diabetic hearts treated with MPG (10 mM)
alone administered 15 min before ischemia and during reperfu-
sion (ff-IR/MPG). To study signaling events, additional experi-
ments were performed with groups of diabetic hearts reperfused
for only 3 or 10 min. Finally, 1 mM palmitoylcarnitine (ff-IR/
C16:0c) was added to the perfusate at the time of reperfusion in
separate experiments to attempt the rescue of IntralipidH
protection in diabetic hearts [11]. Additional diabetic hearts were
perfused aerobically to measure the effects of IntralipidHon
mitochondrial respiratory chain complex activities and to quantify
the acylcarnitine tissue content. Some diabetic hearts were used to
collect apical fibers to measure inhibitor titration curves for
complex IV (cytochrome c oxidase) and mitochondrial hydrogen
peroxide (H2O2) release. These data were compared with results
measured in healthy age-matched hearts [11]. All hearts were
immediately frozen in liquid nitrogen with Wollenberger clamps
and stored at 280uC for subsequent molecular analyses.
Aconitase assay for the determination of ROS production
in mitochondrial matrix of perfused hearts
Aconitase activity was evaluated according to the protocols of
Gardner et al. [20] in mitochondria isolated from perfused hearts
collected after 3 min of reperfusion. Mitochondria were isolated in
the presence of 5 mM sodium citrate to protect aconitase from
oxidation. Mitochondrial preparations were diluted to 0.1 mg/ml
in 50 mM Tris-HCl, pH 7.4 containing 0.05% Triton X-100.
Aconitase activity was assayed as the rate of NADP+ reduction
(extinction coefficient for NADPH at 340 nm is 0.00622 mM21 ?
cm21) at 37uC in a reaction mixture containing 50 mM Tris-Cl
(pH 7.4), 5 mM sodium citrate, 0.6 mMMnCl2, 0.2 mM NADP
+,
1 U/ml isocitrate dehydrogenase, and 0.1 mg/ml mitochondrial
protein. One unit of aconitase converts 1.0 nmol of citrate to
isocitrate per minute at 37uC.
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Citrate synthase (CS) activity
As a measure of mitochondrial content, the activity of the
mitochondrial matrix marker enzyme citrate synthase (CS) was
measured at 412 nm by monitoring the formation of thionitro-
benzoate, as previously described [21].
Amplex Red assay for the determination of mitochondrial
H2O2 release in permeabilized cardiac fibers
To assess mitochondrial H2O2 emission capacity from collected
cardiac fibers, we determined H2O2 production under non-
respiring conditions (no ADP) and under active oxidative
phosphorylation (5 mM ADP) using a combination of pyruvate
(5 mM)/malate (2 mM) and succinate (10 mM) as substrates to
ensure full operation of the citric acid cycle, as well as to provide
both NADH and FADH2 to feed electrons through complexes I
and II, respectively, of the mitochondrial electron transport chain.
H2O2 production was measured using the Amplex Red method
(Invitrogen, Carlsbad, CA) [22]. Horseradish peroxidase (HRP;
2 U/ml) catalyzed the reaction between Amplex Red (20 mM) and
H2O2 in the presence of exogenously added superoxide dismutase
(10 U/ml), forming the fluorophore resorufin, which was moni-
tored at excitation/emission wavelengths of 540/590 nm. H2O2
standard curves were generated for each independent experiment,
to calculate the cumulative mitochondrial H2O2 production from
the resorufin signal. H2O2 production at each time point was then
determined by calculating the rate of change in H2O2 concentra-
tion over 20 min. Background rates of fluorescence change in the
absence of added substrates were subtracted for each experiment.
At the end of each experiment, cardiac fibers were homogenized
for CS activity assays. H2O2 production rate was expressed as
pmol/min/IU CS activity.
High-resolution respirometry in permeabilized cardiac
fibers
Respiration measurements were performed in saponin-permea-
bilized fibers prepared from freshly excised left ventricular apex of
of either perfused or unperfused hearts, using the Oroboros
Oxygraph 2K system (Oroboros, Innsbruck, Austria) [11,18].
Measurements were conducted in an assay buffer comprising
110 mM sucrose, 60 mM K-lactobionate, 20 mM taurine,
0.5 mM EGTA, 3 mM MgCl2?6H2O, 10 mM KH2PO4,
20 mM HEPES, and 1 g/L bovine serum albumin (pH 7.1,
30uC). Mitochondrial respiration was measured in the presence of
5 mM ADP or absence of ADP (leak respiration) using substrates
for complexes I, II, III, and IV as follows. Complex I: pyruvate
(5 mM)/malate (2 mM); complex II: succinate (10 mM); complex
III: decylubiquinol (0.5 mM); complex IV: ascorbate (2 mM)/
tetramethylphenylenediamine dihydrochloride (TMPD; 0.5 mM).
Substrates used together with the inhibition of complex I by
rotenone (0.5 mM), complex II by malonate (2 mM) complex III
by antimycin A (2.5 mM), and complex IV by azide (100 mM)
provided complex-specific flux measurements. All respiratory data
were normalized to CS activity as a marker for mitochondrial
content (nmol O/s/CS). Inhibition of complex IV by palmitoyl-
carnitine was assessed by measuring oxygen consumption in the
presence of ascorbate/TMPD and 5 mM ADP and titrating
palmitoylcarnitine. To measure the effects of sevoflurane on
mitochondrial respiratory chain complex activities, saponin-
permeabilized fibers freshly prepared from early diabetic hearts
were exposed to 0.35 mM sevoflurane dissolved in dimethyl
sulfoxide, equivalent to the clinically used concentration of
1 MAC (minimum alveolar concentration) sevoflurane [23]. Rates
of oxygen consumption were normalized to those measured in the
presence of dimethyl sulfoxide alone (solvent control).
Determination of tissue triglyceride content
After chloroform/methanol extraction of lipids from cardiac
tissue, triglyceride content was quantified colorimetrically with the
enzymatic assay kit L-Type Triglyceride M (Wako Pure Chemical
Industries, Richmond VA, USA). The colorimetric assay was
performed in the presence of 3:2 tert-butyl alcohol:Triton X-100/
methyl alcohol (1:1) mixture.
Mass spectrometry for acylcarnitine profiling
Tissue levels of acylcarnitine species were measured using
electrospray ionization tandem mass spectrometry [24]. Acylcar-
nitines were extracted from heart tissue with methanol and
quantified using eight isotopically labeled internal standards
(Cambridge Isotopes Laboratories, Andover, MA). Precursor ions
of m/z 85 in the mass range of m/z 150 to 450 were acquired on a
PE SCIEX API 365 LC-ESI-MS/MS instrument (AppliedBiosys-
tems, Foster City, CA) [24].
Carnitine palmitoyl transferase (CPT) activity
Total CPT (CPT-I and CPT-II) activity was determined using
mitochondria isolated from frozen heart tissues, according to
Boudina et al. [25]. The reaction was performed with 20 mg
mitochondria in a total of 200 mL reaction volume at 37uC. CPT-
II activity was measured using an identical reaction as for total
CPT activity, but in the presence of 10 mM malonyl-CoA to
inhibit CPT-I activity. CPT-I activity was then calculated as the
difference between total CPT and CPT-II activity.
Immunoblotting
Frozen heart tissue was homogenized in ice-cold buffer
containing 50 mM Tris (pH 8.0), 150 mM NaCl, and 1% NP-
40, and supplemented with protease and phosphatase inhibitor
cocktail mix (Sigma-Aldrich). The homogenate was centrifuged at
1000 g for 10 min at 4uC. The resulting supernatant was collected
for protein concentration determination and used for immuno-
blotting in sodium dodecyl sulfate polyacrylamide gel electropho-
resis. Protein concentration was measured by Bradford assay. The
primary antibodies (Akt, pAkt, ERK1/2, pERK1/2, all from Cell
Signaling Technology, Danvers, MA) were polyclonal rabbit
antibodies. Mouse monoclonal anti-COX IV antibody (clone
20E8C12, ab14744, mitochondrial loading control), polyclonal
rabbit anti-COXIV isoform 2 (ab70112), and polyclonal rabbit
anti-UCP3 (ab3477) were purchased from Abcam Inc. (Cam-
bridge, MA, USA). Polyclonal goat anti-ANT (N-19) was
purchased from Santa Cruz Biotechnology Inc. (Dallas, TX,
USA). Immunoreactivity was visualized by horseradish peroxi-
dase-conjugated antibodies using a peroxidase-based chemilumi-
nescence detection kit (ECL) (PerkinElmer, Woodbridge, Ontario,
Canada). The intensity of the bands was quantified by two
individuals (PHL, EL) independent of each other using ImageJ
software (http://rsbweb.nih.gov/ij/).
Statistical analysis
Values are given as mean (SD) [or mean (SEM) for the
concentration-response curves of complex IV inhibition to avoid
overlap] or median (25th, 75th percentile) depending on the
underlying data distribution for the indicated number of
independent observations. The significance of differences in
hemodynamic variables among groups was determined by
repeated measures analysis-of-variance (RM-ANOVA) followed
Loss of Intralipid H Cardioprotection in Diabetes
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by the Student-Newman-Keuls method for posthoc analysis. For
comparisons involving two independent groups, Student t-test or
Mann-Whitney rank sum test (two-tailed) were used, depending on
the underlying data distribution. For comparisons involving
multiple groups, analysis-of-variance (ANOVA) followed by the
Student-Newman-Keuls Multiple Comparison Procedure was
used. Differences are considered significant if p,0.05. SigmaPlot
(version 12.0; Systat Software, Inc., Chicago, IL) was used for the
analyses. The inhibitory effect of palmitoylcarnitine on respiratory
chain complex IV activity was measured by the global curve fitting
routine implemented in SigmaPlot. Comparison between concen-
tration-response curves and concentration-response parallelism
(i.e., one curve shifted to the right or up as compared to the other)
were measured using the F-test [26].
Results
After 6 weeks of fructose feeding, rats reliably exhibited
increased fasting plasma glucose, insulin, and triglyceride levels
and reduced quantitative insulin sensitivity check index values
consistent with type-2 diabetes (Table 1) [17]. In addition,
fructose-fed rats showed increased diastolic and systolic blood
pressure (Table 1). Hearts of fructose-fed rats exhibited fat
overload as measured by triglyceride tissue content and C16:1/
C16 and C18:1/C18 ratios (‘‘desaturation index’’) (Table 1) [27].
Early type-2 diabetic hearts lose protection by IntralipidH
but not by sevoflurane against ischemia-reperfusion
injury
We evaluated the impact of IntralipidH administration on
recovery of LVW in early diabetic hearts, and compared this effect
with that of the volatile anesthetic sevoflurane, which has been
shown to be effective in healthy and diseased hearts [13,18]. Early
diabetic hearts were subjected to 15 min of ischemia and 30 min
of reperfusion. Administration of IntralipidH at the onset of
reperfusion did not provide any protection (Figure 1A and Table
S1). IntralipidH-treated early diabetic hearts also showed signifi-
cant reduction in postischemic coronary perfusion (Table S1). In
contrast, peri-ischemic administration of 2 vol.-% sevoflurane to
the perfusate 15 min before ischemia and during reperfusion
markedly improved functional recovery, showing its preserved
ability to protect early diabetic hearts against ischemia-reperfusion
injury (Table S1). Contrary to the effects of IntralipidH treatment,
coronary perfusion was preserved in sevoflurane-treated hearts
(Table S1). Sevoflurane-protected early diabetic hearts showed
increased oxidative phosphorylation compared to unprotected, i.e.
IntralipidH-treated, hearts as measured by mitochondrial oxygen
consumption using both glucose- and fatty acid-derived substrates
(Table 2). Similar to our previous findings in healthy hearts [11],
IntralipidH did not contribute to substrate metabolism in the early
diabetic heart (Figure S1).
Differential ROS-dependent activation of reperfusion
injury salvage kinases (RISK) in IntralipidH- and
sevoflurane-treated early type-2 diabetic hearts
Next, we wanted to know whether protection by sevoflurane
would be ROS-dependent and whether reperfusion injury salvage
kinases would be differentially activated in IntralipidH- and
sevoflurane-treated early diabetic hearts. Functional recovery by
sevoflurane was abolished by concomitant administration of MPG,
a reactive oxygen species scavenger (LVW(equilibration) =
8.161.5 mmHg*L/min; LVW(reperfusion) = 1.860.6 mmHg*L/
min; please see Table S1). The temporal activation of Akt and
ERK1/2 in tissue samples collected at 3 and 10 min of reperfusion
was measured by immunoblotting. Akt phosphorylation was
significantly increased in 3 and 10 min samples of sevoflurane-
treated but not IntralipidH-treated diabetic hearts (Figure 1B).
ERK1/2 activity was increased in 3 and 10 min samples of both
IntralipidH- and sevoflurane-treated hearts (Figure 1C). However,
since MPG abolished activation of Akt but not ERK1/2 in
sevoflurane-treated hearts, ERK1/2 appears not to be causally
Table 1. Effects of fructose feeding on physiological and metabolic parameters.
healthy ff P-value
Initial body weight [g] 250 (7) 251 (8) 0.76
Final body weight [g] 558 (29) 520 (36) 0.015
Heart wet weight/body weight 0.0040 (0.0038; 0.0042) 0.0040 (0.0038; 0.0040) 0.303#
Systolic blood pressure [mmHg] 117 (6) 148 (7) ,0.001
Diastolic blood pressure [mmHg] 68 (7) 103 (11) ,0.001
Plasma fasting glucose [mg*dL21] 114 (110; 116) 143 (136; 150) ,0.001
Plasma fasting insulin [ng*mL21] 0.42 (0.18) 1.12 (0.34) ,0.001
QUICKI 0.32 (0.02) 0.27 (0.01) ,0.001
Plasma triglycerides [mg*mL21] 74 (71; 102) 161 (147; 187) ,0.001
Cardiac tissue triglycerides [mmol/g dry wt] 6.35 (2.01) 7.74 (2.29) 0.016
C16:1c/C16:0c desaturation ratio 0.34 (0.04) 0.57 (0.20) 0.024
C18:1c/C18:0c desaturation ratio 7.81 (0.82) 9.64 (0.93) 0.011
Data are presented as mean (SD) or median (25th; 75th percentile). N = 8–16 (N = 30 for tissue triglycerides). # Mann-Whitney Rank Sum Test.
healthy, age-matched control rats (fed standard chow and water).
ff, rats fed standard chow and 10% fructose added to the drinking water.
QUICKI, quantitative insulin sensitivity check index.
C16:1c, cardiac tissue levels of palmitoleoylcarnitine.
C16:0c, cardiac tissue levels of palmitoylcarnitine.
C18:1c, cardiac tissue levels of oleoylcarnitine.
C18:0c, cardiac tissue levels of stearoylcarnitine.
doi:10.1371/journal.pone.0104971.t001
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involved in cardioprotection of this model (Figure 2A and 2B).
MPG alone did not affect Akt or ERK1/2.
Loss of electron transport chain inhibition and ROS
generation in IntralipidH- but not sevoflurane-treated
early type-2 diabetic hearts
Previous work has shown that the formation of ROS during
early reperfusion is the unifying mediator of cardioprotection by
IntralipidH [11] and sevoflurane [19,28] in healthy hearts. In the
case of sevoflurane, ROS is produced at complex I of the
respiratory chain via the attenuation of complex I activity
[29,30,31], a result that was confirmed and extended in this study
to early diabetic hearts (Figure 3A). Sevoflurane attenuated
complex I activity of early diabetic hearts (for complete data on
mitochondrial respiration in the presence of sevoflurane, see Table
S2) and significantly reduced aconitase activity in tissue samples
collected after 3 min of reperfusion, consistent with increased
formation of ROS (Figure 3B). As for IntralipidH, we previously
demonstrated that ROS formation in healthy hearts is the result of
complex IV inhibition [11]. When we assessed the respiratory
complex activities in time-matched aerobically perfused early
diabetic hearts, we did not observe any inhibition of complex IV
activity by IntralipidH (Figure 3C) (for complete respiratory
complex activities of time-matched aerobically perfused diabetic
hearts see Table S3). In healthy hearts, IntralipidHsignificantly
inhibited complex IV by 27% [11]. There was no loss of aconitase
activity in IntralipidH-treated diabetic hearts (Figure 3B) at early
reperfusion, an observation which was further confirmed by
Amplex Red assay (Figure 3D).
Switch in subunit IV of cytochrome c oxidase and
increased uncoupling as potential mechanisms
underlying loss of IntralipidH-mediated cardioprotection
in early type-2 diabetic hearts
We previously identified the fatty acid intermediate palmitoyl-
carnitine as pivotal in IntralipidH-mediated cardioprotection in
healthy hearts acting through complex IV inhibition and ROS
generation [11]. We hypothesized that fatty acid uptake into
mitochondria would be reduced in early diabetic hearts. Indeed,
the enzymatic activity of carnitine palmitoyltransferase 1 was
significantly reduced in early diabetic hearts reperfused in the
presence of IntralipidH (Figure 4A). Reperfused early diabetic
hearts also exhibited reduced mitochondrial uptake of the most
abundant C18:2 constituent of IntralipidH, when compared to
healthy hearts (Figures S2 and S3, which provide an overview of
the main finding from tissue acylcarnitine profiling). Aerobically
perfused IntralipidH-treated diabetic hearts further exhibited
reduced long-chain acylcarnitine tissue concentrations compared
with healthy hearts, confirming reduced mitochondrial fatty acid
uptake (please see Figure S3). To circumvent the fatty acid uptake
limitation in fructose-fed rats, we supplied palmitoylcarnitine –
which readily crosses the mitochondrial membrane – at the onset
of reperfusion. Contrary to findings in healthy hearts, no
enhancement of functional recovery was achieved with 1 mM
palmitoylcarnitine (LVW(equilibration) = 8.560.3 mmHg*L/min;
LVW(reperfusion) = 1.760.7 mmHg*L/min; n= 4). We then
tested if palmitoylcarnitine could still inhibit complex IV in the
same way as it does in healthy hearts [11]. Palmitoylcarnitine
titrations revealed a significantly different concentration-inhibition
curve (overall comparison p(F-test) = 0; left-right shift p(F-
test) = 1027; up-down shift p(F-test) = 1.6*1029) in diabetic cardiac
fibers, resulting in higher IC50 values in diabetic hearts compared
to healthy hearts (Figure 4B) [11]. Interestingly, there was no
difference in complex IV inhibition by cyanide (which binds to the
heme a3-CuB binuclear center) between healthy and diabetic
hearts (data presented in Figure S4), implying a different binding
site for palmitoylcarnitine.
Early diabetic hearts expressed higher levels of subunit IV-2 of
complex IV (Figure 5A), which was previously shown to enhance
complex IV activity during metabolic stress [32], potentially
accounting for the different inhibition characteristics. Uncoupling
protein-3 levels were significantly increased in early diabetic hearts
when normalized to nuclear encoded complex IV (Figure 5B).
Increased levels of subunit IV-2 of complex IV and uncoupling
protein-3 in diabetic hearts were also confirmed when normalized
to adenine nucleotide translocase, a protein of the inner
mitochondrial membrane (see Figure S5). Citrate synthase activity
measurements in healthy control hearts and hearts of fructose-fed
rats (17.262.2 vs 14.461.5 mmol/mL/min/mg, p,0.001, N= 20)
Figure 1. Left ventricular work and protection signaling in IntralipidH- and sevoflurane-treated early type-2 diabetic hearts. Panel A:
average left ventricular work (LVW) during equilibration (striped columns) and reperfusion (30 min: solid columns) in untreated early diabetic hearts
(ff-IR: N = 10), early diabetic hearts exposed to 2 vol.-% sevoflurane (ff-IR/SEV; N= 10), and early diabetic hearts treated with 1% IntralipidH at the onset
of reperfusion (ff-IR/IL; N = 6). Data are mean 6 SD. Panel B: p-Akt (at Ser473) to total Akt immunoblots from tissue samples collected 3 min and
10 min after the onset of reperfusion. Panel C: p-ERK1/2 (at Thr202/Tyr204) to total ERK1/2 immunoblots from the same tissues. ff-IR(time), untreated
hearts exposed to 15 min of ischemia and 3 min (ff-IR/3 min) or 10 min (ff-IR/10 min) of reperfusion, respectively; ff-IR/SEV(time), hearts exposed to
ff-IR(time) and 2 vol.-% sevoflurane; ff-IR/IL(time), hearts exposed to ff-IR(time) and 1% IntralipidH at the onset of reperfusion. *, significantly different
from ff-IR(time); **, significantly different from ff-IR(time) and ff-IR/IL(time); #, significantly different from ff-IR/IL(time). Data are mean 6 SD. N= 4
hearts in each group.
doi:10.1371/journal.pone.0104971.g001
Table 2. Mitochondrial respiration in saponin-skinned cardiac fibers harvested at the end of the ischemia-reperfusion protocols.
Protocol Substrates ff-IR ff-IR/IL ff-IR/SEV P-value
Glucose oxidation protocol pyruvate/malate 11.4 (1.9) 11.5 (2.0) 15.8 (2.2)* ,0.001
Fatty acid oxidation protocol palmitoylcarnitine/malate 3.0 (1.0) 2.6 (0.5) 3.6 (0.8)# 0.028
Mitochondrial respiration was measured in the presence of glucose-derived (pyruvate/malate) or fat-derived substrates (palmitoylcarnitine/malate). The measured
oxygen consumption (normalized to citrate synthase activity) is expressed as nmol O2 s
21/CS. Data are presented as mean (SD). *, significantly increased compared to all
other groups;#, significantly increased compared to ff-IR/IL.
ff-IR, hearts from fructose-fed rats exposed to ischemia-reperfusion (IR) without treatment (N = 10); ff-IR/SEV, hearts from fructose-fed rats exposed to IR with sevoflurane
(2 vol.-%) conditioning (N = 10); ff-IR/IL, hearts from fructose-fed rats exposed to IR with Intralipid (1%) treatment at the onset of reperfusion (N = 6).
doi:10.1371/journal.pone.0104971.t002
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confirmed the presence of fewer mitochondria in diabetic hearts.
Evidence for enhanced uncoupling activity in fructose-fed rats can
be seen in our experiments from (i) increased mitochondrial leak
respiration in cardiac fibers of IntralipidH-treated early diabetic
hearts collected at 3 min of reperfusion (Figure 5C); and (ii)
increased leak respiration without changes in ROS production
(Figure 5D). In contrast, IntralipidH treatment enhanced ROS
production without increasing mitochondrial leak in healthy hearts
(Figure 5D).
Discussion
We chose the fructose-induced type-2 diabetes rat model
because it reflects an early stage of diabetes due to its reversibility
up to twelve weeks of feeding and the absence of severe
maladaptive changes as observed in genetic, inbred or type-1
diabetes models [15]. Rats exposed to fructose-feeding for 6 weeks
consistently exhibited characteristics of type-2 diabetes such as
increased fasting glucose, hyperinsulinemia, hyperlipidemia, insu-
lin resistance, and arterial hypertension [15]. In this dietary model
of early type-2 diabetes, our study shows that IntralipidH
treatment, a promising therapy against ischemia-reperfusion injury
in healthy rats [11], completely lost its protection. We attribute this
to the loss of IntralipidH-induced protective ROS signaling as a
consequence of reduced sensitivity of complex IV to inhibition by
palmitoylcarnitine and enhanced mitochondrial uncoupling. In
contrast, sevoflurane, a clinically used drug, is still able to induce
sufficient amounts of protective ROS via complex I inhibition in
early diabetic hearts to activate reperfusion injury salvage kinases.
Hence, ROS is a prerequisite to effective cardioprotection even in
early diabetes, and its production depends on the impact of the
cardioprotective agent on mitochondrial ROS production.
Metabolic inhibition at the level of the electron transport chain
recently emerged as a unifying mechanism of cardioprotection
[33]. At the onset of reperfusion, a surge of substrates and oxygen
rapidly reestablish respiration causing a burst of ROS, Ca2+
overload and permeability transition pore opening. However,
ROS can have both protective and deleterious effects depending
on the time, location, and amount released. The burst of ROS
released during reperfusion is associated with injury causing
irreversible damage to proteins. Small amounts of ROS produced
right at the onset of reperfusion have a signaling role and trigger
cardioprotection against ischemia-reperfusion injury [34]. In the
concept of ‘‘metabolic shut-down and gradual wake-up’’, inhib-
itors of the electron transport chain slow down electron flux at
early stages of reperfusion and thus facilitate an initial early peak of
protective ROS well before the noxious ROS burst, which
activates reperfusion injury salvage kinases and GSK3b, ultimately
preventing mitochondrial permeability transition [19,35]. While
ischemic bouts inhibit complex I and II [33], volatile anesthetics
specifically inhibit complex I [29,30,31]. We have recently shown
that high-dose IntralipidH treatment through its intermediate
palmitoylcarnitine specifically inhibits complex IV (as with nitric
oxide, carbon monoxide, and hydrogen disulfide) in healthy hearts
and provides protection by generation of protective ROS [11].
How does palmitoylcarnitine inhibit complex IV and
enhance ROS production in healthy hearts?
Our current experiments suggest 2 because of no differences in
cyanide inhibition between diabetic and healthy hearts 2 that
Figure 2. ROS-dependent protection signalling in sevoflurane-treated early type-2 diabetic hearts. Panel A: representative
immunoblots showing blunted activation of Akt in early diabetic hearts subjected to 15 min of ischemia and 10 min reperfusion in the presence
of 2 vol.-% sevoflurane and concomitantly treated with the antioxidant MPG. *, significantly different from sevoflurane-treated hearts. Panel B: ERK
activation is not mediated by ROS (same tissue samples as in Panel A). ff-IR(10 min), untreated hearts exposed to 15 min of ischemia and 10 min of
reperfusion; ff-IR/SEV(10 min), hearts exposed to ff-IR(10 min) and 2 vol.-% sevoflurane; ff-IR/SEV+MPG(10 min), sevoflurane-treated hearts exposed
to 15 min of ischemia and 10 min of reperfusion with N-(2-mercaptopropionyl) glycine (MPG; 10((M). ff-IR/MPG(10 min), hearts exposed to 15(min of
ischemia and 10(min of reperfusion in the presence of MPG alone. Data are mean 6 SD. N = 4–6 hearts in each group.
doi:10.1371/journal.pone.0104971.g002
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palmitoylcarnitine is inhibiting complex IV in healthy hearts via a
mechanism distinct from that of cyanide’s inhibition of complex
IV. Fatty acids are known to bind to complex IV to directly modify
its catalytic activity [36] or to modify the binding of ligands, such
as cytochrome c [37], and to modulate electron flux in the electron
transport chain. In fact, fatty acids, and many amphiphatic
molecules which are sterically similar to acylcarnitines, bind to a
conserved amphiphatic ligand binding region [38]. Complex IV
inhibition per se does not increase ROS production from this
complex itself, but more so from the reduction of redox centers in
complex I or III [32]. It is thus possible that the amphiphatic
palmitoylcarnitine binds to this recently identified regulatory site
of complex IV. Alternatively, fatty acids (and possibly also their
derivatives) modify cytochrome c binding to complex IV [37].
Oxidized cytochrome c is a powerful superoxide scavenger within
the mitochondrial intermembrane space, and a shift from oxidized
to reduced cyctochrome c, as expected by altered binding of
cytochrome c to complex IV, would reduce ROS scavenging and
increase ROS production.
How does fructose-induced early type-2 diabetes abolish
protective ROS signaling?
Mitochondria from early diabetic hearts show increased H2O2
levels compared to healthy mitochondria as measured by the
Amplex Red assay [11], consistent with the concept of increased
oxidative stress being a hallmark of insulin resistance and diabetes.
Figure 3. Respiratory chain inhibition and ROS production at the onset of reperfusion. Panel A: sevoflurane inhibits complex I in diabetic
cardiac fibers. Polarographic measurements of oxygen consumption in sevoflurane-treated (0.35(mM) diabetic cardiac fibers oxidizing the complex I
substrates pyruvate+malate. *, significantly different from solvent control. DMSO, dimethyl sulfoxide (0.1%) used as solvent for sevoflurane. Panel B:
loss of aconitase activity in sevoflurane-treated but not in IntralipidH-treated early diabetic hearts. #, significantly different from untreated and
IntralipidH-treated early diabetic hearts. Panel C: polarographic measurements of oxygen consumption in cardiac fibers collected from IntralipidH-
treated diabetic hearts oxidizing the complex IV substrates N,N,N9,N9-tetramethyl-p-phenylenediamine/ascorbate. ff-AER, hearts with time-matched
aerobic perfusion. ff-AER/IL, hearts with time-matched aerobic perfusion treated with 1% IntralipidH. Panel D: hydrogen peroxide (H2O2) emission
capacity during early reperfusion. ff-IR(3 min), untreated hearts exposed to 15 min of ischemia and 3 min of reperfusion; ff-IR/IL(3 min), hearts
exposed to 15 min of ischemia and 3 min of reperfusion treated with 1% IntralipidH at the onset of reperfusion. Basal, without substrates. +subst,
with added substrates (pyruvate/malate/succinate). Data are mean 6 SD. N= 4–5 hearts per group.
doi:10.1371/journal.pone.0104971.g003
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Thus, the increased uncoupling protein-3 levels in diabetic
mitochondria contribute to the maintenance of a normal
membrane potential below the threshold of excessive ROS
generation [39,40]. Uncoupling proteins have been shown to be
activated by ROS [41], products of lipid peroxidation [42], or
fatty acids, albeit in vitro [43,44] as oxidative stress-mitigating
mechanism. Our data show increased leak respiration without
changes in ROS production during early reperfusion in the
presence of IntralipidH, and support the notion that fatty acids
released from IntralipidH may greatly enhance the activity of
Figure 4. Mitochondrial fatty acid uptake and complex IV inhibition by palmitoylcarnitine in early type-2 diabetic hearts. Panel A:
carnitine palmitoyltransferase 1 and 2 (CPT1 and CPT2, respectively) activity at the onset of reperfusion in healthy (h-IR/IL(3 min)) and early diabetic
(ff-IR/IL(3 min) hearts treated with 1% IntralipidH. *, significantly different from healthy hearts. N = 10 hearts in each group. Panel B: concentration-
dependent inhibition of complex IV by palmitoylcarnitine (C16:0c) in permeabilized cardiac fibers of healthy (reproduced from reference [19]) and
fructose-fed (ff) rats. Complex IV inhibition is given as relative decrease in oxygen consumption. IC50, concentration of palmitoylcarnitine that reduces
the respiration rate by 50%. N= 5–6 hearts per group. Data are or mean 6 SD (panels A) or mean 6 SEM (panel B).
doi:10.1371/journal.pone.0104971.g004
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Figure 5. Mechanisms underlying loss of protective ROS signaling in early type-2 diabetic hearts. Panel A: increase in isoform 2 of
complex IV (COX) subunit IV (COX IV-2) in cardiac mitochondria from fructose-fed (ff) rats as compared to healthy rats. Panel B: uncoupling protein 3
(UCP 3) is increased in cardiac mitochondria of fructose-fed (ff) rats as compared with healthy rats. COX, cytochrome c oxidase. Panel C: leak
respiration (normalized to citrate synthase (CS) activity) with pyruvate as measured by polarography in permeabilized cardiac fibers from fructose-fed
rats collected at reperfusion. Panel D: relationship between hydrogen peroxide (H2O2) emission capacity determined by Amplex Red assay and leak
respiration (normalized to citrate synthase activity) with pyruvate measured by polarography in permeabilized cardiac fibers from healthy
(reproduced from reference [19]) and fructose-fed (ff) rats collected at reperfusion. ff-IR(3 min), untreated hearts exposed to 15 min of ischemia and
3 min of reperfusion; ff-IR/IL(3 min), hearts exposed to 15 min of ischemia and 3 min of reperfusion with 1% IntralipidH at the onset of reperfusion;
Arrows illustrate the opposing response to IntralipidH treatment in healthy vs. early diabetic hearts (see manuscript for details). **, significantly
increased from healthy. Data are mean 6 SD. N = 4–5 hearts in each group.
doi:10.1371/journal.pone.0104971.g005
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uncoupling protein-3 (either directly or via lipid peroxidation), and
thus efficiently annihilate the early increase in ROS production in
diabetic mitochondria. Long-term exposure of myocytes to high
glucose can impair complex IV activity via enzymatic O-
GlcNAcylation [45]. Thus the diabetic heart may counteract this
loss of complex IV activity by switching complex IV from subunit
IV-1RIV-2, to directly increase the catalytic activity of complex
IV. Increased levels of subunit IV-2 are associated with increased
complex IV activity and reduced ROS production [46,47]. Under
normal conditions, there is very little subunit IV-2 relative to
subunit IV-1 in the heart. However, under metabolic stress, i.e.
increased ROS production or hypoxia [46,48,49,50], the relative
expression of IV-2/IV-1 is augmented as IV-2 expression is
increased along with the rapid degradation of subunit IV-1. These
findings potentially explain the observed difference in the
inhibition characteristics by palmitoylcarnitine in our experiments.
ROS signaling in the context of anesthetic-induced
protection of diabetic hearts
We and others have shown that cardioprotection by volatile
anesthetics is ROS-dependent [19,51,52], and we recently
extended this paradigm to IntralipidH-treated cardioprotection
[11]. Our current data on IntralipidH- and sevoflurane-mediated
protection in early diabetic hearts confirm the importance of ROS
in cardioprotection. Therefore, short-term administration of
antioxidants during early stages of type-2 diabetes diminishes
rather than restores cardioprotection. Although our results are
different from an earlier study which reported loss of protection by
sevoflurane postconditioning in the prediabetic state of the leptin-
mutant Zucker obese rat model [53], the fact that protection in
this model could not be rescued by cyclosporine A, a mPTP
opener, points to severe downstream defects associated with this
genetic mutant, which may not necessarily reflect conditions in
early diabetes.
Pre- and postischemic administration of sevoflurane mimics the
clinical situation where volatile anesthetics are usually given before
and after a potentially ischemic challenge to the heart [54].
Although IntralipidH is unable to protect the diabetic heart against
ischemia-reperfusion injury, sevoflurane may be still protective in
patients with early type-2 diabetes. This may be particularly true
in patients with reasonably well-controlled metabolism, which is
indeed the case for the majority of surgical patients.
Limitations of the study
It is possible that the timing of sevoflurane administration might
have also contributed to the more efficient protection of
sevoflurane compared with IntralipidH. However, since pre- and
postischemic sevoflurane administration in diabetic hearts did not
produce higher ROS levels than IntralipidH 3 min after the onset
of reperfusion in healthy myocardium, as evidenced by a 25% loss
of aconitase activity [11], it appears unlikely that the preischemic
component of sevoflurane administration, i.e. the timing itself,
accounts for sevoflurane’s more efficient protection in diabetic
hearts. Also, pre-ischemic Akt activity in sevoflurane-treated
diabetic hearts showed no difference compared to untreated
hearts, emphasizing the importance of Akt activation during early
reperfusion. In fact, previous reports in healthy hearts show equal
protection by postischemic vs pre- and postischemic sevoflurane
administration in rat hearts in vivo [55]. Whether this also applies
to early diabetic hearts needs further investigation.
In summary
Our experiments show that effective cardioprotection by
IntralipidH is lost in early type-2 diabetes, whereas sevoflurane
still retains its beneficial properties. We discover that effective
cardioprotection in early type-2 diabetes depends on the inhibition
site of the electron transport chain and the impact of the
cardioprotective agent on mitochondrial ROS production.
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